Butyrate and IBS
What 3 graded rows on butyrate agree on for IBS, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Butyrate page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Butyrate page, with its PubMed record.
Your question
Butyrate and IBS
3 rows · 169 peopleThey agree: all 3 rows found an improvement.
- CGrade C× 2
- DGrade D× 1
- Rows
- 3
- Trials
- 3
- People
- 169
What the rows share
From the rowsThe best-graded row, grade C, is a randomized trial of 66 people (2013) and found an improvement.
The rows run from 51 to 66 people, published from 2013 to 2026: 3 single studies.
The rows
3 improved- CGrade CIrritable bowel syndrome symptoms (add-on to standard therapy) · Improved
RCT · n 66 · 2013 · Adults with IBS on standard drug therapy for at least 3 months
Not stated in the abstract · 12 weeks
Pain during defaecation fell at 4 weeks and urgency and bowel habit improved at 12 weeks versus placebo; abdominal pain, flatulence and overall symptom severity did not change significantly.
- CGrade CIBS symptoms in children · Improved
RCT · n 51 · 2025 · Children aged 4 to 17 with IBS (Rome IV)
500 mg/day · 8 weeks, then 4 weeks off
Treatment success (pain score down at least 50%) was 73% with butyrate versus 3.8% with placebo; pain and symptom scores stayed lower after the washout.
- DGrade DIBS symptoms and glucose control in type 2 diabetes · Improved
RCT · n 52 · 2026 · Adults with type 2 diabetes meeting Rome IV criteria for IBS
1.5 g/day · 12 weeks
The butyrate group reported less abdominal pain, diarrhoea and bloating and had lower weight, HbA1c and HOMA-IR, with fewer positive hydrogen breath tests; the placebo group did not change.